Next Century Growth Investors LLC Grows Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Next Century Growth Investors LLC raised its position in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 77.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 943,597 shares of the company’s stock after buying an additional 412,280 shares during the period. Next Century Growth Investors LLC’s holdings in Adaptive Biotechnologies were worth $15,324,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of ADPT. Westfield Capital Management Co. LP purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at about $65,942,000. Ameriprise Financial Inc. lifted its position in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its position in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the last quarter. Lord Abbett & CO. LLC lifted its position in shares of Adaptive Biotechnologies by 151.2% during the fourth quarter. Lord Abbett & CO. LLC now owns 3,080,759 shares of the company’s stock valued at $50,032,000 after buying an additional 1,854,355 shares during the last quarter. Finally, PBU The Pension Fund of Early Childhood & Youth Educators purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at about $26,801,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Julie Rubinstein sold 30,941 shares of the stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total value of $458,855.03. Following the transaction, the chief operating officer owned 434,188 shares in the company, valued at approximately $6,439,008.04. This represents a 6.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 83,332 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $14.41, for a total transaction of $1,200,814.12. Following the completion of the transaction, the chief executive officer owned 2,217,781 shares in the company, valued at approximately $31,958,224.21. This trade represents a 3.62% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 516,654 shares of company stock worth $7,509,691. 5.70% of the stock is owned by company insiders.

Adaptive Biotechnologies Stock Down 6.0%

Shares of Adaptive Biotechnologies stock opened at $17.60 on Friday. The firm has a market capitalization of $2.82 billion, a P/E ratio of -53.33 and a beta of 2.15. The company has a 50 day moving average price of $14.57 and a 200 day moving average price of $15.68. Adaptive Biotechnologies Corporation has a 52 week low of $9.90 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the company earned ($0.20) EPS. Adaptive Biotechnologies’s quarterly revenue was up 35.1% on a year-over-year basis. As a group, research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADPT has been the subject of several analyst reports. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. TD Cowen increased their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.